The approval of tirzepatide by the United States Food and Drug Administration (FDA) marks an important milestone in the field of medicine for weight loss and the fight against obesity.
Until this moment, tirzepatide was marketed under the name Mounjaro for the treatment of type 2 diabetes and had already become an increasingly used option for weight loss, despite not yet having specific approval to treat obesity.
Tirzepatide will be sold under the brand name Zepbound for use in adults with a body mass index (BMI) of at least 30, or a BMI of 27 or higher if the patient also has other weight-related health problems, such as heart disease.
This significantly expands the scope of tirzepatide as a treatment for obesity, as it targets a broader group of patients.
Interest in the obesity market has been notable, attracting the attention of Wall Street and generating expectations in the pharmaceutical industry. Obesity and overweight are significant health problems that are associated with serious conditions such as heart disease, stroke and diabetes, making effective treatments highly demanded.
The approval of tirzepatide for the treatment of obesity represents an advance in the fight against this growing health epidemic and provides doctors with a new tool to help patients achieve and maintain a healthy weight.
Eli Lilly's entry into this market demonstrates the company's commitment to developing therapeutic solutions for significant health problems and, at the same time, reflects the growing interest in obesity treatment worldwide.
With information from: El Economista.
Receive all industry news in our weekly Newsletter Dialéctica Científica.